0001562180-24-004949.txt : 20240611
0001562180-24-004949.hdr.sgml : 20240611
20240611165748
ACCESSION NUMBER: 0001562180-24-004949
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20240610
FILED AS OF DATE: 20240611
DATE AS OF CHANGE: 20240611
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: COLA MICHAEL F
CENTRAL INDEX KEY: 0001188940
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36544
FILM NUMBER: 241036519
MAIL ADDRESS:
STREET 1: 435 DEVON PARK BUILDING 800
CITY: WAYNE
STATE: PA
ZIP: 19087-1945
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sage Therapeutics, Inc.
CENTRAL INDEX KEY: 0001597553
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-299-8380
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0508
4
2024-06-10
false
0001597553
Sage Therapeutics, Inc.
SAGE
0001188940
COLA MICHAEL F
C/O SAGE THERAPEUTICS, INC.
215 FIRST STREET
CAMBRIDGE
MA
02142
true
false
false
false
false
Stock Option (Right to Buy)
10.90
2024-06-10
4
A
false
12500.00
0.00
A
2034-06-09
Common Stock
12500.00
12500.00
D
The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan in accordance with Sage's Non-Employee Director Compensation Program. The option will vest in full upon the earlier to occur of June 10, 2025 or the day immediately prior to the 2025 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date.
Brandon Marsh, as Attorney-in-Fact for Michael F Cola
2024-06-11
EX-24
2
mcolapoa.txt
POA2024
POWER OF ATTORNEY
I, the undersigned, hereby authorize and designate Anne Marie
Cook (Senior Vice President, General Counsel), Kimi Iguchi (Chief
Financial Officer) and Brandon Marsh (Director, Corporate Counsel),
for as long as they remain employees of Sage Therapeutics, Inc., and
Stuart Falber of WilmerHale, each acting singly, or their successors
in role, to take the following actions, acting as my agent and
attorney-in-fact, with full power of substitution:
(1) to prepare and sign on my behalf any Form 4 or Form 5
pursuant to Section 16 of the Securities Exchange Act of 1934,
as amended, and to file the same with the Securities and
Exchange Commission, Nasdaq, NYSE, and each stock exchange on
which shares of Common Stock or other securities of Sage
Therapeutics, Inc. are listed, as required by law;
(2) to prepare and sign on my behalf any Form 144 pursuant to the
Securities Act of 1933, as amended, and to file the same with
the Securities and Exchange Commission, Nasdaq, NYSE, and each
stock exchange on which shares of Common Stock or other
securities of Sage Therapeutics, Inc. are listed, as required by
law; and
(3) take any other action necessary or proper in connection with
the foregoing.
Unless earlier revoked under the next sentence, this Power of
Attorney shall remain in effect as long as I am a director or
executive officer of Sage Therapeutics, Inc., and shall not be
affected by my subsequent disability or incompetence. I may revoke
this Power of Attorney by written notice delivered, in person or by
nationally recognized courier, to the attention of the Senior Vice
President, General Counsel of Sage Therapeutics, Inc.
Name: Michael Cola
Date: 5/29/2024